Many Achaogen, Inc.(AKAO) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Achaogen Inc was Initiated by Stifel on Feb 7, 2017 to Buy, Price Target of the shares are set at $27.Company shares were Reiterated by Wedbush on Feb 1, 2017 to Outperform, Raises Price Target to $ 23 from a previous price target of $19 .Achaogen Inc was Initiated by Guggenheim to Buy on Jan 23, 2017. Achaogen Inc was Initiated by Leerink Partners to Outperform on Jan 4, 2017. Achaogen Inc was Upgraded by Needham on Dec 13, 2016 to Buy, Price Target of the shares are set at $19.
Company has reported several Insider transactions to the SEC, on Jan 30, 2017, Blake Wise (Chief Operating Officer) sold 1,431 shares at 16.78 per share price.On Jan 30, 2017, Tobin Schilke (Chief Financial Officer) sold 955 shares at 16.78 per share price.On Jan 30, 2017, Gary Loeb (General Counsel) sold 521 shares at 16.78 per share price.
Achaogen Inc Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.20. Analyst had a consensus of $-0.61. The company had revenue of $16.05 million for the quarter, compared to analysts expectations of $9.10 million. The companys revenue was up 258.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.48 EPS.
Achaogen, Inc. (NASDAQ:AKAO) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 1.1 by 10 Brokerage Firm. 9 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating.
Achaogen, Inc. (NASDAQ:AKAO): The stock price is expected to reach $ 22.17 in the short term. The number of analysts agreeing with this consensus is 6. The higher estimate for the short term price target is at $27 while the lower estimate is at $18. The standard deviation of the price stands at $3.49.
Achaogen, Inc. (NASDAQ:AKAO) rose 0.7% or 0.15 points on Tuesday and made its way into the gainers of the day. After trading began at $21.39 the stock was seen hitting $21.7199 as a peak level and $21 as the lowest level. The stock ended up at $21.66. The daily volume was measured at 862,368 shares. The 52-week high of the share price is $21.83 and the 52-week low is $2.5875. The company has a market cap of $757 million.
Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California.